Table 5.
Effects of increased 5-HT1BR stimulation on psychostimulant abuse-related behaviors.
| Model | Treatment (selectivity) | Dose of treatment | Effect (Psychostimulant dose); Species; Schedule; Further comments | Reference |
|---|---|---|---|---|
| Cocaine: SA maintenance | RU24968:5-HT1B/1AR agonist (7-fold; Macor et al., 1990) | 1 mg/kg, SC 1–3 mg/kg, SC 0.3-3 mg/kg, SC |
↑ ascending limb (0.03 mg, IV); rats; FR5 ↓ descending limb (0.125 mg, IV); rats; FR5 ↑ (0.125 mg, IV); rats; PR |
(Parsons et al., 1998) |
| CP94253: 5-HT1B/1D/1AR agonist (24-fold; Koe et al., 1992) | 1 mg/kg, SC 1–3 mg/kg, SC 1–3 mg/kg, SC |
↑ ascending limb (0.03 mg, IV); rats; FR5 ↓ descending limb (0.125 mg, IV); rats; FR5 ↑ (0.125 mg, IV); rats; PR+ |
(Parsons et al., 1998) | |
| 5.6 mg/kg, SC | ↓ descending limb (0.1875–0.75 mg/kg, IV); rats; FR5 | (Pentkowski et al., 2009) | ||
| 5.6 mg/kg, SC | ↓ descending limb (0.75); rats; FR5+ | (Pentkowski et al., 2012b) | ||
| 5–7.5 mg/kg, IP | ↓ descending limb (0.125–0.5 mg, IV); rats; FR5+ | (Przegalinski et al., 2007) | ||
| CP93129: 5-HT1BR agonist: (146-fold; Macor et al., 1990) | 10 μg, ICV 3–10 μg, ICV |
↑ ascending limb (0.03 mg, IV); rats; FR5 ↓ descending limb (0.125 mg, IV); rats; FR5 |
(Parsons et al., 1998) | |
| Viral mediated 5-HT1BR gene transfer (elevated 5-HT1BR expression) | ~200,000 infective units infused into the NAc shell | ↑ ascending limb (0.032–0.1 mg/kg, IV), Ø descending limb (0.32–1 mg/kg, IV); rats; FR5 ↑ (0.75 mg/kg, IV); rats; PR |
(Pentkowski et al., 2012a) | |
| Amphetamine: SA maintenance | CP94253 | 2.5–5 mg/kg, IP | ↓ descending limb (0.06–0.12 mg/kg, IV); rats; FR5+ | (Miszkiel et al., 2012) |
| Cocaine: SA protracted abstinence | CP94253 | 5.6 mg/kg, SC | ↓ ascending/descending limbs (0.075–0.75 mg/kg, IV); rats; FR5+ ↓ (0.375 mg/kg, IV); rats; PR+ |
(Pentkowski et al., 2012b) |
| Viral mediated 5-HT1BR gene transfer | ~200,000 infective units infused into the NAc shell | ↓ (0.75 mg/kg); rats; PR | (Pentkowski et al., 2012a) | |
| Cocaine seeking, early abstinence (<48hr) | CP94253 | 5.6 mg/kg, SC | Ø (1 day), ↓ (5 days); rats; response-contingent cues; FR1 | (Pentkowski et al., 2012b) |
| Cocaine seeking, protracted abstinence | CP94253 | 3–10 mg/kg, SC | Ø rats; no cues | (Pentkowski et al., 2009) |
| RU24968 | 1–3 mg/kg, SC | ↓ rats; response-contingent cues; FR1+ | (Acosta et al., 2005) | |
| CP94253 | 5.6–10 mg/kg, SC | ↓ rats; response-contingent cues; FR1 | (Pentkowski et al., 2009) | |
| 5 mg/kg, IP | ↓ rats; response-contingent cues; FR1 | (Przegalinski et al., 2008) | ||
| Viral mediated 5-HT1BR gene transfer | ~200,000 infective units infused into the NAc shell | ↓ rats; response-contingent cues; FR1; with history of extinction or abstinence only | (Pentkowski et al., 2012a) | |
| Cocaine-primed reinstatement of cocaine seeking* | CP94253 | 5.6–10 mg/kg, SC 10 mg/kg, SC |
↓ (prime: 10 mg/kg, IP); rats ↓ (prime: 2.5 mg/kg, IP); rats |
(Pentkowski et al., 2009) |
| 5 mg/kg, IP 2.5 mg/kg, IP |
↓ (prime: 10 mg/kg, IP); rats ↑ (prime: 2.5 mg/kg, IP); rats |
(Przegalinski et al., 2008) | ||
| RU24968 | 1–3 mg/kg, SC | ↓ (prime: 10 mg/kg, IP); rats+ | (Acosta et al., 2005) | |
| Viral mediated 5-HT1BR gene transfer | ~200,000 infective units infused into the NAc shell | ↓ (prime: 10 mg/kg, IP); rats | (Pentkowski et al., 2012a) |
Key:↑: increased compared with control. ↓: decreased compared with control. Ø: no effect compared with control. SA: self-administration. FR: fixed ratio schedule of reinforcement. PR: progressive ratio schedule of reinforcement. NAc: Nucleus accumbens.
*
tests carried out after protracted abstinence (<48h).
+
agonist effect blocked by a 5-HT1BR antagonist